Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection

Journal of the Chinese Medical Association

Volumn 67, Issue 4, 2004, Pages 161-167

  Wu, Chung Jen ^a   Hsu, Ping I ^a   Lo, Gin Ho ^a   Lo, Ching Chu ^a   Lin, C K Chiun Ku ^a   Shie, Chang Bih ^a   Peng, Nan Jing ^b   Tseng, Hui Hwa ^b   Jou, Huei Shu ^b   Tsai, Pei Min ^a   Chen, Angela ^c   Chen, Jin Liang ^d   Lai, Kwok Hung ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Cetraxate; Eradication; Helicobacter pylori; Pantoprazole; Therapy

Indexed keywords

AMOXICILLIN; CETRAXATE; CLARITHROMYCIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; NAUSEA; PILOT STUDY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SMOKING HABIT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TASTE DISORDER; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLARITHROMYCIN; DIZZINESS; DRUG THERAPY, COMBINATION; ENDOSCOPES, GASTROINTESTINAL; EXANTHEMA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OMEPRAZOLE; PILOT PROJECTS; PROSPECTIVE STUDIES; SULFOXIDES; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 3042570870     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hunt RH, Lam SK. Helicobacter pylori: from art to a science. J Gastroenterol Hepatol 1998;13:21-8.
2. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized controlled study. Ann Intern Med 1992; 116:705-8.
3. Hsu PI, Lai KH, Lo GH, Tseng HH, Lo CC, Chen HC, et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective 2 year follow up study of 209 patients. Gut 2002;51:15-20.
4. Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin North Am 2000;29:819-27.
5. Isaacson PG. Recent developments in our understanding of gastric lymphomas. Am J Surg Pathol 1996:20(suppl.):1-7.
6. Hsu PI, Lai KH, Tseng HH, Lo GH, Lo CC, Lin CK, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001;15:195-201.
7. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
8. Megraud F, Lamouliatte H. The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43.
9. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of 3 US multicenter, double-blind trials. Am J Gastroenterol 2000; 95:3393-8.
10. Lo CC, Hsu PI, Lo GH, Lai KH, Lo GH, Chan HH, et al. The effect of lansoprazole-based triple therapy and bismuth-based triple therapy on the eradication of Helicobacter pylori in Chinese. J Intern Med Taiwan 1999;10:71-6.
11. Ishimori A, Yamagata S, Taima T. Effect of p-hydroxyphenyl-propionic ester of tranexamic acid hydrochloride (cetraxate) on peptic ulcer. Drug Res 1979;29:1625-32.
12. Miyoshi A, Okuhara T, Kishimoto S. Clinical efficacy evaluation of cetraxate against peptic ulcer. Jpn Arch Intern Med 1977;24:1-28.
13. Adachi K, Suetsugu H, Moriyama N, Kazumori H, Kawamura A, Fujishiro H, et al. Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers. J Gastroenterol Hepatol 2001;16:1211-6.
14. Miyake T, Murakami M, Sakai M. Defense mechanism of the gastric mucosa. Jpn Arch Intern Med 1982;29:28-50.
15. Lazaratos S, Kashimura H, Nakahara A, Fukutomi H, Osuga T, Miyauchi T, et al. Endothelin-1-induced gastric ulcer is attenuated by cetraxate. Life Sci 1993;53:123-8.
16. Kimura K, Goto Y, Ogihara Y, Taniguchi Y, Satoh K. The relations between cetraxate and anti-H. pylori activity. Clin Res 1999;76:1210-6.
17. Kamada T, Haruma K, Miyoshi E, Mihara M, Kitadai Y, Yoshihara M, et al. Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin and clarithromycin increases the eradication rate of Helicobacter pylori in smokers. Aliment Pharmacol Ther 2000;14:1089-94.
18. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Klein JPD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
19. Adachi K, Ishihara S, Hashimoto T, Hirakawa K, Nigaki M, Takashima T, et al. Efficacy of sucrafate for Helicobacter pylori eradication triple therapy in comparison with lansoprazole-based regimen. Aliment Pharmacol Ther 2000;14:919-22.
20. Hsu PI, Lai KH, Tseng HH, Liu YC, Yen MY, Lin CK, et al. Correlation of serum immunoglobulin G Helicobacter pylori antibody titers with histologic and endoscopic findings in patients with dyspepsia. J Clin Gastroenterol 1997;25:587-91.
21. Hsu PI, Lai KH, Tseng HH, Lin CK, Lo GH, Cheng JS, et al. Risk factors for presentation with bleeding in patients with Helicobacter pylori-related peptic ulcer diseases. J Clin Gastroenterol 2000;30:386-91.
22. Tseng HH, Hsu PI, Chen HC, Lai KH, Lo GH. Compartment theory in Helicobacter pylori-associated gastric carcinogenesis. Anticancer Res 2003;23:3223-9.
23. 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Dig Liver Dis 2003;35:73-7.
24. 13C]-urea breath test for the diagnosis of Helicobacter pylori infection in patients with non-ulcer dyspepsia. J Gastroenterol Hepatol 2000;15:284-9.
25. Kurebayashi YI, Ikeda T, Osada Y. Cytoprotective action of cetraxate against HCl-ethanol-induced gastric lesion in rats. Jpn J Pharmacol 1988;46:17-25.
26. Lind T, Megraud F, Unge P, Bayerdorffer E, O'morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
27. Tachi K, Goto H, Hayakawa T, Sugiyama S. Prevention of water immersion stress-induced gastric lesions through the enhancement of nitric synthase activity in rats. Aliment Pharmacol Ther 1996;10:97-103.
28. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, et al. Lansoprazole, a novel benzimidazole protoen pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6.
29. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Scand J Gastroenterol 1994;29:1070-5.
30. Megraud F, Doermann HP. Clinical relevance of resistant strains of Heliocobacter pylori: a review of current data. Gut 1998;43(suppl 1):S61-5.
31. Ching CK, Leung KP, Yung RW, Lam SK, Wong BC, Lai KC, et al. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 1996;38:675-8.
32. Moshkowitz M, Konikoff FM, Peled Y, Brill S, Hallak A, Tiomny E, et al. One week triple therapy with omeprazole, clarithromycin and tinidazole for Heliocobacter pylori: differing efficacy in previously treated patients. Aliment Pharmacol Ther 1996;10:1015-9.
33. Lin CK, Hsu PI, Lai KH, Lo GH, Tseng HH, Lo CC, et al. One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. J Clin Gastroenterol 2002;34:547-51.
34. Culter AF, Schubert T. Patients factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroneterol 1993;88:505-9.
35. Endoh K, Kauffman GLJ, Leung FM. Mechanisms of aggravation of mucosal injury by intravenous nicotine in rat in stomach. Am J Physiol 1991;261:1037-42.
36. Gustavson L, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effects of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995;39:2078-83.